Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systematic analysis of homozygous autosomal copy number losses in exomes improves diagnostic yield and uncovers ultra-rare recessive disorders.

European journal of human genetics : EJHG·2026

Same author

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice.

The pharmacogenomics journal·2026

Same author

Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.

The pharmacogenomics journal·2026

Same author

Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Nature genetics·2026

Same author

From science to service-overcoming clinical implementation barriers to population genomic screening.

European journal of human genetics : EJHG·2026

Same author

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross-sectional analysis.

British journal of clinical pharmacology·2026

Same journal

Implementing systems- and organisational-level change to advance gender equality in healthcare leadership: a mixed-methods implementation protocol.

Implementation science communications·2026

Same journal

Harmonizing intervention, context, and implementation strategies with Context-Driven Co-Design (CD2).

Implementation science communications·2026

Same journal

Advancing health equity through the development of a scholars training program in implementation science.

Implementation science communications·2026

Same journal

Participatory approaches for tailoring implementation strategies in healthcare settings: a scoping review of contemporary literature (2019-2024).

Implementation science communications·2026

Same journal

Correction: Matters arising: a commentary on "Failing to succeed: advancing mechanistic understanding of implementation strategies through retrospective and prospective use of causal pathway diagrams" by Austad et al. 2025.

Implementation science communications·2026

Same journal

The PIECES multi-site comparative case study protocol: mixed methods implementation evaluation of adapting, implementing and tailoring primary cancer prevention programmes in diverse contexts.

Implementation science communications·2026

See all related articles

Search research articles

Home
Implementing Pharmacogenetic-guided Prescribing In General Practice: A Qualitative Process Evaluation.

Home
Implementing Pharmacogenetic-guided Prescribing In General Practice: A Qualitative Process Evaluation.

Related Experiment Video

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Implementing pharmacogenetic-guided prescribing in general practice: a qualitative process evaluation.

Lisa Brunton¹, William Newman^2,3, John McDermott^2,3

¹Centre for Primary Care and Health Services Research, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, University of Manchester, Williamson Building, Oxford Road, Manchester, M13 9PL, UK. lisa.brunton@manchester.ac.uk.

Implementation Science Communications

|June 26, 2026

View abstract on PubMed

Summary

This summary is machine-generated.

Pharmacogenetic-guided prescribing shows promise in general practice, but implementation faces barriers like workload and research study constraints. Tailoring delivery helps, but wider integration into routine care is limited.

Related Experiment Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

Implementation Science
Pharmacogenomics
General Practice Research

Background:

Adverse drug reactions cause poor patient outcomes and increase healthcare costs.
Pharmacogenetic-guided prescribing enhances medication safety and efficacy.
The PROGRESS study evaluates pharmacogenetic-guided prescribing in primary care settings.

Purpose of the Study:

To explore barriers and enablers of implementing pharmacogenetic-guided prescribing in general practice.
To understand the clinician perspective on pharmacogenetic integration.
To assess the viability and utility of pharmacogenetic-guided prescribing.

Main Methods:

Conducted 29 online semi-structured interviews with 30 general practice staff.
Included 20 general practices across England participating in the PROGRESS study.

Utilized a modified framework approach for data analysis, informed by CFIR and NPT.

Main Results:

Clinicians recognized the value of pharmacogenetic-guided prescribing but selectively applied it.
Implementation was often limited to the research study scope, with minimal planning for routine practice.
Local tailoring of pharmacogenetics delivery facilitated implementation, while research study confines and workload posed barriers.

Conclusions:

General practice staff understood the benefits of pharmacogenetic-guided prescribing.
Wider practice engagement beyond staff awareness was minimal.
Pharmacogenetic integration was perceived as a research proof-of-concept rather than routine practice normalization.